//
A. Lescoat
S. Jouneau
B. Crestani
G. Riemekasten
Y. Kondoh
V. Smith
N. Patel
J. Huggins
C. Stock
M. Gahlemann
M. Alves
C. Denton
CHU South Hospital, Internal Medicine, Rennes, France
Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, CHU Rennes, Rennes, France
Hôpital Bichat, Pneumologie, Paris, France
University Hospital Charité, Rheumatology and Clinical Immunology, Berlin, and University Hospital Schleswig-Holstein, Rheumatology, Lübeck, Germany
Tosei General Hospital, Respiratory Medicine and Allergy, Seto, Japan
Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium
Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Division of Pulmonary, Allergy, and Critical Care Medicine, New York, NY, United States of America
Medical University of South Carolina, Charleston, South Carolina, United States
Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany
Boehringer Ingelheim (Schweiz), GmbH, Basel, Switzerland,
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,
Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom
France
Germany
Japan
Belgium
United States
Switzerland
United Kingdom
Boehringer Ingelheim
Autoimmune (AI)
Scleroderma
N/A
Nintedanib
N/A
Randomized
Placebo Control
Non Randomized
NA
N/A
Airbnb
N/A